data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Yield
How to Buy Corporate Bonds
How to Buy Treasury Bonds
How to Invest in Real Estate Online
Money
Compare Online Brokers
Stock Brokers
Forex Brokers
Futures Brokers
Crypto Brokers
Options Brokers
ETF Brokers
Mutual Fund Brokers
Index Fund Brokers
Bond Brokers
Short Selling Brokers
Stock Apps
All Broker Reviews
Insurance
Auto
Home
Medicare
Life
Vision
Dental
Business
Pet
Health
Motorcycle
Renters
Workers Comp
Top Stocks
Penny Stocks
Stocks Under $5
Stocks Under $10
Stocks Under $20
Stocks Under $50
Stocks Under $100
Alternative Investing
Invest in Art
Invest in Watches
Invest in Land
Invest in Real Estate
Invest in Wine
Invest in Gold
Mortgages
Refinance
Purchase
Find a Mortgage Broker
Alts
Alternative Investment Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
How to Invest in Jewelry
Best Real Estate Crowdfunding Platforms
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Get Started
Is Bitcoin a Good Investment?
Is Ethereum a Good Investment?
What is Blockchain
Best Altcoins
How to Buy Cryptocurrency?
DeFi
Crypto and DeFi 101
What is DeFi?
Decentralized Exchanges
Best DeFi Yield Farms
Digital Securities
NFTs
NFT Release Calendar
What is a Non-Fungible Token (NFT)?
How to Buy Non-Fungible Tokens (NFTs)
CryptoPunks Watchlist
Are NFTs a Scam or a Digital Bubble?
Best In Crypto
Best Crypto Apps
Best Crypto Portfolio Trackers
Best Crypto Day Trading Strategies
Best Crypto IRA
Best Cryptocurrency Scanners
Best Business Crypto Accounts
Best Crypto Screeners
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Gamida Cell Ltd

(NASDAQ:GMDA)

Perks Buy Compare Brokers

$0.3168

-0.0202[-5.99%]

Last update: 5:32PM (Delayed 15-Minutes)
Get Real Time Here

$0.3168

0[0.00%]

After-Hours

Perks Buy Compare Brokers

Open0.336	Close0.317
Vol / Avg.3.105M / 1.669M	Mkt Cap42.020M
Day Range0.309 - 0.340	52 Wk Range0.218 - 2.510

0

Latest News for Gamida Cell Stock (NASDAQ:GMDA)

Gamida Cell Stock (NASDAQ: GMDA)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Monday, November 20, 2023

Small-Caps Grossly Underperform Broader Market Amid This Red Flag: 5 Stocks On The Scanner
Shanthi Rexaline - Nov 20, 2023, 6:13AM

Wednesday, November 15, 2023

Gamida Cell Filed For Mixed Shelf Of Up to $150M
Charles Gross - Nov 15, 2023, 5:31PM
Piper Sandler Maintains Overweight on Gamida Cell, Lowers Price Target to $2-Report Released on 14th Nov 2023
Benzinga Newsdesk - Nov 15, 2023, 10:34AM
Piper Sandler Maintains Overweight on Gamida Cell, Lowers Price Target to $2
Benzinga Newsdesk - Nov 15, 2023, 10:33AM
HC Wainwright & Co. Maintains Buy on Gamida Cell, Lowers Price Target to $5
Benzinga Newsdesk - Nov 15, 2023, 7:45AM

Tuesday, November 14, 2023

Why Beyond Air Shares Are Trading Lower By Around 37%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Nov 14, 2023, 2:05PM
Gamida Cell shares are trading lower after the company reported worse-than-expected Q3 revenue results.
Benzinga Newsdesk - Nov 14, 2023, 1:57PM
Earnings Scheduled For November 14, 2023
Benzinga Insights - Nov 14, 2023, 8:23AM
Gamida Cell Q3 EPS $(0.01) vs $(0.17) Est., Revenue $673K vs $2.37M Est.
Benzinga Newsdesk - Nov 14, 2023, 7:08AM
Recap: Gamida Cell Q3 Earnings
Benzinga Insights - Nov 14, 2023, 7:05AM

Tuesday, October 17, 2023

Gamida Cell's Blood Cancer Candidate Shows Encouraging Anti-Tumor Activity In Heavily Pretreated Patients
Vandana Singh - Oct 17, 2023, 8:34AM

Monday, October 16, 2023

Gamida Cell Reports Preliminary Data From Phase 1 Study Of Natural Killer Cell Therapy Candidate GDA-201
Benzinga Newsdesk - Oct 16, 2023, 4:39PM

Monday, October 09, 2023

Gamida Cell Issues Update On Israel Operations
Benzinga Newsdesk - Oct 9, 2023, 2:01PM

Thursday, September 28, 2023

JMP Securities Reiterates Market Outperform on Gamida Cell, Maintains $6 Price Target
Benzinga Newsdesk - Sep 28, 2023, 8:49AM

Wednesday, September 27, 2023

Gamida Cell Ltd. Announces That The First Patient Has Received A Stem Cell Transplant With Omisirge
Benzinga Newsdesk - Sep 27, 2023, 4:40PM

Wednesday, August 16, 2023

HC Wainwright & Co. Reiterates Buy on Gamida Cell, Maintains $11 Price Target
Benzinga Newsdesk - Aug 16, 2023, 6:52AM

Tuesday, August 15, 2023

Analyst Ratings for Gamida Cell
Benzinga Insights - Aug 15, 2023, 9:00AM
Needham Reiterates Buy on Gamida Cell, Maintains $6 Price Target
Benzinga Newsdesk - Aug 15, 2023, 4:13AM

Monday, August 14, 2023

Gamida Cell Q2 EPS $(0.31) Misses $(0.18) Estimate, Cash & Equivalents As Of Quarter-End Pegs At $54.075M
Benzinga Newsdesk - Aug 14, 2023, 7:04AM
Earnings Scheduled For August 14, 2023
Benzinga Insights - Aug 14, 2023, 6:45AM

Friday, August 11, 2023

Gamida Cell's Earnings: A Preview
Benzinga Insights - Aug 11, 2023, 11:01AM

Tuesday, July 11, 2023

Gamida Cell Ltd. Announces Data Published In Transplantation And Cellular Therapy Suggest Antiviral Protection After Transplantation With Co's Omisirge
Happy Mohamed - Jul 11, 2023, 8:19AM

Friday, June 30, 2023

Expert Ratings for Gamida Cell
Benzinga Insights - Jun 30, 2023, 4:00PM
Needham Reiterates Buy on Gamida Cell, Maintains $6 Price Target
Benzinga Newsdesk - Jun 30, 2023, 4:22AM

Monday, May 22, 2023

Gamida Cell Appoints Terry Coelho As CFO, Effective Immediately
Benzinga Newsdesk - May 22, 2023, 8:05AM
HC Wainwright & Co. Reiterates Buy on Gamida Cell, Maintains $11 Price Target
Benzinga Newsdesk - May 22, 2023, 6:11AM

Friday, May 19, 2023

Analyst Expectations for Gamida Cell's Future
Benzinga Insights - May 19, 2023, 11:02AM
JMP Securities Maintains Market Outperform on Gamida Cell, Lowers Price Target to $6
Benzinga Newsdesk - May 19, 2023, 6:07AM

Tuesday, May 16, 2023

Oppenheimer Maintains Outperform on Gamida Cell, Lowers Price Target to $6
Benzinga Newsdesk - May 16, 2023, 9:08AM
Needham Reiterates Buy on Gamida Cell, Maintains $6 Price Target
Benzinga Newsdesk - May 16, 2023, 5:56AM

Monday, May 15, 2023

Gamida Cell Expects Its Current Cash And Cash Equivalents To Support Its Ongoing Operating Activities Into 2024
Benzinga Newsdesk - May 15, 2023, 4:20PM
Gamida Cell Q1 EPS $(0.27) Vs. $(0.34) Prior Year
Benzinga Newsdesk - May 15, 2023, 4:14PM
Earnings Scheduled For May 15, 2023
Benzinga Insights - May 15, 2023, 5:32AM

Friday, May 12, 2023

Earnings Outlook For Gamida Cell
Benzinga Insights - May 12, 2023, 2:02PM

Thursday, April 20, 2023

Despite Early Approval Of Omidubicel, Analyst Says Longer-Term Financial Overhang Remains For Gamida Cell
Vandana Singh - Apr 20, 2023, 3:39PM
Why MIND Technology Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Apr 20, 2023, 8:07AM

Wednesday, April 19, 2023

Why Travelers Companies Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Lisa Levin - Apr 19, 2023, 1:04PM
Where Gamida Cell Stands With Analysts
Benzinga Insights - Apr 19, 2023, 12:00PM
HC Wainwright & Co. Maintains Buy on Gamida Cell, Raises Price Target to $11
Benzinga Newsdesk - Apr 19, 2023, 10:20AM
Gamida Cell shares are trading lower after the company announced pricing of a $23 million public offering of securities.
Benzinga Newsdesk - Apr 19, 2023, 9:43AM
Gamida Cell Announces Pricing Of $22.8M Public Offering Of 17.5M Shares Of Common Stock And Warrants At A Price Of $1.30/Share And Exercise price of $1.35/Warrant
Happy Mohamed - Apr 19, 2023, 8:19AM
Why Sonnet BioTherapeutics Shares Are Trading Lower By Around 13%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Apr 19, 2023, 8:13AM
Gamida Cell Announces Launch of Public Offering of Securities; No Size Or Amount Disclosed
Happy Mohamed - Apr 19, 2023, 7:16AM

Tuesday, April 18, 2023

Dow Edges Higher; Goldman Sachs Posts Upbeat Earnings
Lisa Levin - Apr 18, 2023, 2:31PM
Why Glory Star New Media Group Shares Are Trading Higher By 122%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Apr 18, 2023, 1:14PM
Gamida Cell shares are trading higher after the company announced it received FDA approval for Omisirge allogeneic cell therapy.
Benzinga Newsdesk - Apr 18, 2023, 8:47AM
Why Digital Brands Group Shares Are Trading Lower By Over 15%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Apr 18, 2023, 8:17AM
Gamida Cell Scores FDA Nod For Cord Blood-Based Cancer Therapy
Vandana Singh - Apr 18, 2023, 6:48AM
HC Wainwright & Co. Reiterates Buy on Gamida Cell, Maintains $5 Price Target
Benzinga Newsdesk - Apr 18, 2023, 6:26AM

Monday, April 17, 2023

Gamida Cell Receives FDA Approval For Omisirge Allogeneic Cell Therapy
Benzinga Newsdesk - Apr 17, 2023, 4:18PM

1
2
3
4
5
6
7
Next
17

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2023 Benzinga | All Rights Reserved